Analyst Price Targets — PRTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 10:30 am | — | Stifel Nicolaus | $19.00 | $9.31 | StreetInsider | Prothena (PRTA) Reiterated at Market Outperform by Citizens After Fireside Chat |
| December 1, 2025 10:38 am | Jason Butler | JMP Securities | $19.00 | $10.75 | TheFly | Prothena price target raised to $19 from $11 at Citizens JMP |
| December 1, 2025 9:32 am | — | Deutsche Bank | $19.00 | $10.75 | StreetInsider | Prothena Corp (PRTA) PT Raised to $19 at Citizens: Discovery Engine Successful |
| October 28, 2025 12:14 pm | Yasmeen Rahimi | Piper Sandler | $36.00 | $11.09 | StreetInsider | Prothena Corp (PRTA) PT Raised to $36 as Piper Sandler Remains Bullish |
| October 28, 2025 10:38 am | — | UBS | $36.00 | $11.31 | TheFly | Prothena price target raised to $36 from $15 at Piper Sandler |
| October 7, 2025 12:32 pm | — | H.C. Wainwright | $20.00 | $9.86 | TheFly | Prothena price target raised to $20 from $14 at H.C. Wainwright |
| September 2, 2025 10:36 am | Jason Butler | JMP Securities | $11.00 | $8.27 | TheFly | Prothena price target lowered to $11 from $29 at Citizens JMP |
| August 14, 2024 7:40 am | Jay Olson | Oppenheimer | $62.00 | $19.77 | StreetInsider | Prothena Corp (PRTA) PT Lowered to $62 at Oppenheimer |
| August 9, 2024 6:27 am | Kennen MacKay | RBC Capital | $24.00 | $19.68 | StreetInsider | Prothena Corp (PRTA) PT Lowered to $24 at RBC Capital |
| May 9, 2024 6:32 am | Kennen MacKay | RBC Capital | $28.00 | $23.03 | StreetInsider | Prothena Corp (PRTA) PT Lowered to $28 at RBC Capital |
Latest News for PRTA
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Officer and Mr. Isaacs to General Counsel and Corporate Secretary. Mr. Malecek is departing in June.
The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for prasinezumab for Parkinson's and BMS-986446 for Alzheimer's disease at AD/PD™ 2026.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM.
Prothena Corporation plc is maintained at a Hold rating due to mixed phase 2 data and long timelines for key programs. PRTA's leading assets, prasinezumab (Parkinson's disease) and coramitug (ATTR-CM), are in phase 3 trials with primary completion expected in 2029. The Bristol-Myers Squibb partnership provides up to $1.55 billion in milestones and royalties, with BMS-986446 in phase 2 for early Alzheimer's.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRTA.
U.S. House Trading
No House trades found for PRTA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.